Does the media favor CRNX or ASND?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 7 mentions for Crinetics Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMMT or CRNX?

In the previous week, Summit Therapeutics had 9 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 16 mentions for Summit Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.36 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BBIO or CRNX?

In the previous week, BridgeBio Pharma had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 7 mentions for Crinetics Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.63 beat Crinetics Pharmaceuticals' score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CRNX or AXSM?

In the previous week, Axsome Therapeutics had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 19 mentions for Axsome Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.33 beat Axsome Therapeutics' score of 0.14 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CRNX or ELAN?

In the previous week, Elanco Animal Health had 11 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 18 mentions for Elanco Animal Health and 7 mentions for Crinetics Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.77 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Crinetics Pharmaceuticals (CRNX) Competitors

$34.97 +1.49 (+4.45%)

Closing price 04:00 PM Eastern

Extended Trading

$34.95 -0.02 (-0.06%)

As of 04:23 PM Eastern

Compare

CRNX vs. ASND, SMMT, BBIO, AXSM, and ELAN

Should you buy Crinetics Pharmaceuticals stock or one of its competitors? MarketBeat compares Crinetics Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crinetics Pharmaceuticals include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Crinetics Pharmaceuticals compare to Ascendis Pharma A/S?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 11 mentions for Ascendis Pharma A/S and 7 mentions for Crinetics Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Ascendis Pharma A/S's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Crinetics Pharmaceuticals currently has a consensus target price of $76.13, indicating a potential upside of 117.69%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 38.53%. Given Crinetics Pharmaceuticals' higher possible upside, equities research analysts clearly believe Crinetics Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	478.86	-$465.32M	-$5.13	N/A
Ascendis Pharma A/S	$814.57M	16.33	-$258M	$8.67	24.59

Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Crinetics Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Crinetics Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Crinetics Pharmaceuticals	$7.70M	478.86	-$465.32M	-$5.13	N/A

Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Summit Therapeutics had 9 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 16 mentions for Summit Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.36 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Summit Therapeutics presently has a consensus target price of $26.05, indicating a potential upside of 82.32%. Crinetics Pharmaceuticals has a consensus target price of $76.13, indicating a potential upside of 117.69%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Crinetics Pharmaceuticals beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BridgeBio Pharma has a net margin of -124.42% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. BridgeBio Pharma's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Crinetics Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.40	-$724.93M	-$3.74	N/A
Crinetics Pharmaceuticals	$7.70M	478.86	-$465.32M	-$5.13	N/A

BridgeBio Pharma has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 7 mentions for Crinetics Pharmaceuticals. BridgeBio Pharma's average media sentiment score of 0.63 beat Crinetics Pharmaceuticals' score of 0.33 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma presently has a consensus price target of $89.59, suggesting a potential upside of 32.37%. Crinetics Pharmaceuticals has a consensus price target of $76.13, suggesting a potential upside of 117.69%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

BridgeBio Pharma beats Crinetics Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Axsome Therapeutics?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Axsome Therapeutics has a net margin of -26.59% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Axsome Therapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	478.86	-$465.32M	-$5.13	N/A
Axsome Therapeutics	$638.50M	19.80	-$183.17M	-$3.73	N/A

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Crinetics Pharmaceuticals currently has a consensus price target of $76.13, indicating a potential upside of 117.69%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 2.29%. Given Crinetics Pharmaceuticals' higher probable upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Axsome Therapeutics had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 19 mentions for Axsome Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.33 beat Axsome Therapeutics' score of 0.14 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Axsome Therapeutics beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Elanco Animal Health has a net margin of -4.95% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Elanco Animal Health's return on equity of 7.42% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Elanco Animal Health	-4.95%	7.42%	3.66%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Crinetics Pharmaceuticals currently has a consensus target price of $76.13, indicating a potential upside of 117.69%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 15.18%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has higher revenue and earnings than Crinetics Pharmaceuticals. Elanco Animal Health is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	478.86	-$465.32M	-$5.13	N/A
Elanco Animal Health	$4.72B	2.59	-$232M	-$0.50	N/A

In the previous week, Elanco Animal Health had 11 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 18 mentions for Elanco Animal Health and 7 mentions for Crinetics Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.77 beat Crinetics Pharmaceuticals' score of 0.33 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRNX vs. The Competition

Export

Metric	Crinetics Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.69B	$2.95B	$6.48B	$11.93B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-6.82	17.78	24.57	23.75
Price / Sales	478.86	419.58	531.63	116.49
Price / Cash	N/A	56.17	26.99	37.23
Price / Book	3.60	3.89	10.53	6.75
Net Income	-$465.32M	$75.85M	$3.56B	$337.35M
7 Day Performance	7.24%	-1.23%	-0.88%	-2.45%
1 Month Performance	-6.70%	-5.10%	1.45%	1.49%
1 Year Performance	8.33%	15.90%	21.50%	24.64%

Crinetics Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRNX Crinetics Pharmaceuticals	3.4649 of 5 stars	$34.97 +4.5%	$76.13 +117.7%	+1.4%	$3.69B	$7.70M	N/A	210	News Coverage
ASND Ascendis Pharma A/S	4.6503 of 5 stars	$218.82 -2.4%	$295.39 +35.0%	+18.9%	$13.98B	$865.78M	25.24	1,189	News Coverage Positive News Analyst Forecast
SMMT Summit Therapeutics	3.2898 of 5 stars	$15.71 -10.4%	$26.05 +65.8%	-31.5%	$13.61B	N/A	N/A	110	Gap Up High Trading Volume
BBIO BridgeBio Pharma	3.7154 of 5 stars	$65.36 -1.4%	$88.90 +36.0%	+74.4%	$12.98B	$502.08M	N/A	400	Insider Trade High Trading Volume
AXSM Axsome Therapeutics	2.1113 of 5 stars	$230.25 -1.8%	$251.26 +9.1%	+110.1%	$12.07B	$708.24M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRNX) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Crinetics Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Crinetics Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Crinetics Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Crinetics Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ASND, SMMT, BBIO, AXSM, and ELAN

How does Crinetics Pharmaceuticals compare to Ascendis Pharma A/S?

Does the media favor CRNX or ASND?

Is CRNX or ASND more profitable?

Do analysts rate CRNX or ASND?

Which has better valuation and earnings, CRNX or ASND?

Which has more risk & volatility, CRNX or ASND?

Do institutionals & insiders believe in CRNX or ASND?

Summary

How does Crinetics Pharmaceuticals compare to Summit Therapeutics?

Which has better earnings and valuation, SMMT or CRNX?

Which has more volatility & risk, SMMT or CRNX?

Do institutionals & insiders believe in SMMT or CRNX?

Does the media favor SMMT or CRNX?

Is SMMT or CRNX more profitable?

Do analysts prefer SMMT or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to BridgeBio Pharma?

Do institutionals and insiders hold more shares of BBIO or CRNX?

Is BBIO or CRNX more profitable?

Which has stronger earnings & valuation, BBIO or CRNX?

Which has more volatility & risk, BBIO or CRNX?

Does the media refer more to BBIO or CRNX?

Do analysts recommend BBIO or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Axsome Therapeutics?

Is CRNX or AXSM more profitable?

Which has higher earnings and valuation, CRNX or AXSM?

Do insiders & institutionals have more ownership in CRNX or AXSM?

Which has more risk & volatility, CRNX or AXSM?

Do analysts rate CRNX or AXSM?

Does the media prefer CRNX or AXSM?

Summary

How does Crinetics Pharmaceuticals compare to Elanco Animal Health?

Is CRNX or ELAN more profitable?

Do institutionals and insiders believe in CRNX or ELAN?

Which has more risk & volatility, CRNX or ELAN?

Do analysts recommend CRNX or ELAN?

Which has preferable valuation & earnings, CRNX or ELAN?

Does the media prefer CRNX or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools